Overview

CAP-Ketamine for Antidepressant Resistant PTSD

Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Phase:
Phase 2
Details
Lead Sponsor:
VA Office of Research and Development
Collaborators:
Brooke Army Medical Center
Minneapolis Veterans Affairs Medical Center
The University of Texas Health Science Center at San Antonio
Treatments:
Antidepressive Agents
Ketamine